# Medicare Program; CY 2027 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Acute Kidney Injury Dialysis (AKI) Payment, and ESRD Quality Incentive Program

> Briefs, arguments, decisions, and more.

URL: https://www.frixlaw.com/law-library/documents/fr%3A2026-12925

## Record

- **Collection:** Federal Register
- **Document type:** Proposed Rule
- **Published:** June 26, 2026
- **Citation:** 91 FR 38784

## Text

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
42 CFR Part 413
[CMS-1846-P]
RIN 0938-AV81
Medicare Program; CY 2027 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Acute Kidney Injury Dialysis (AKI) Payment, and ESRD Quality Incentive Program

AGENCY:

Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS).

ACTION:

Proposed rule.

SUMMARY:

This proposed rule would update and revise the End-Stage Renal Disease (ESRD) Prospective Payment System for calendar year 2027. This rule also proposes to update the payment rate for renal dialysis services furnished by an ESRD facility to individuals with acute kidney injury. In addition, this rule proposes to update the requirements for the ESRD Quality Incentive Program.

DATES:

To be assured consideration, comments must be received at one of the addresses provided below, by August 24, 2026.

ADDRESSES:

In commenting, please refer to file code CMS-1846-P.

Comments, including mass comment submissions, must be submitted in one of the following three ways (please choose only one of the ways listed):

1.
Electronically.
You may submit electronic comments on this regulation to
https://www.regulations.gov/docket/CMS-2026-2245.
Follow the “Submit a comment” instructions.

2.
By regular mail.
You may mail written comments to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS-1846-P, P.O. Box 8010, Baltimore, MD 21244-8010.

Please allow sufficient time for mailed comments to be received before the close of the comment period.

3.
By express or overnight mail.
You may send written comments to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS-1846-P, Mail Stop C4-26-05, 7500 Security Boulevard, Baltimore, MD 21244-1850.

For information on viewing public comments, see the beginning of the
SUPPLEMENTARY INFORMATION
section.

FOR FURTHER INFORMATION CONTACT:

ESRDPayment@cms.hhs.gov
or Abigail Ryan (410) 786-4343, for issues related to the ESRD Prospective Payment System (PPS) and coverage and payment for renal dialysis services furnished to individuals with acute kidney injury (AKI).

ESRDApplications@cms.hhs.gov,
for issues related to applications for the Transitional Drug Add-on Payment Adjustment (TDAPA) or Transitional Add-On Payment Adjustment for New and Innovative Equipment and Supplies (TPNIES).

QNETSUPPORT-ESRD@cms.hhs.gov,
for issues related to the ESRD Quality Incentive Program (QIP).

SUPPLEMENTARY INFORMATION:

Inspection of Public Comments:
All comments received before the close of the comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following website as soon as possible after they have been received:
https://www.regulations.gov.
Follow the search instructions on that website to view public comments. CMS will not post on
Regulations.gov
public comments that make threats to individuals or institutions or suggest that the commenter will take actions to harm an individual. CMS continues to encourage individuals not to submit duplicative comments. We will post acceptable comments from multiple unique commenters even if the content is identical or nearly identical to other comments.

Plain Language Summary:
In accordance with 5 U.S.C. 553(b)(4), a plain language summary of this rule may be found at
https://www.regulations.gov/.

Current Procedural Terminology (CPT) Copyright Notice:
Throughout this proposed rule, we use CPT® codes and descriptions to refer to a variety of services. We note that CPT® codes and descriptions are copyright 2020 American Medical Association (AMA). All Rights Reserved. CPT® is a registered trademark of the AMA. Applicable Federal Acquisition Regulations (FAR) and Defense Federal Acquisition Regulations (DFAR) apply.

I. Executive Summary

A. Purpose

This rule proposes changes related to the End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) and payment for renal dialysis services furnished to individuals with acute kidney injury (AKI). This rule also proposes to update requirements for the ESRD Quality Incentive Program (QIP).

1. End-Stage Renal Disease (ESRD) Prospective Payment System (PPS)

On January 1, 2011, we implemented the ESRD PPS, a case-mix adjusted, bundled PPS for renal dialysis services furnished by ESRD facilities as required by section 1881(b)(14) of the Social Security Act (the Act), as added by section 153(b) of the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA) (Pub. L. 110-275). Section 1881(b)(14)(F) of the Act, as added by section 153(b) of MIPPA, and amended by section 3401(h) of the Patient Protection and Affordable Care Act (the Affordable Care Act) (Pub. L. 111-148), established that beginning calendar year (CY) 2012, and each subsequent year, the Secretary of the Department of Health and Human Services (the Secretary) shall annually increase payment amounts by an ESRD market basket percentage increase, reduced by the productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act. This rule proposes updates to the ESRD PPS for CY 2027, including a routine proposal to rebase and revise the ESRD Bundled (ESRDB) market basket. This rule also proposes to modify the ESRD PPS base rate to reflect the incorporation of phosphate binders
1

into the ESRD PPS bundled payment and to make budget neutral changes to certain ESRD PPS payment adjustments, including proposed changes to the case mix adjusters for pediatric ESRD patients, changes to the low-volume payment adjustment (LVPA), and modifications to the TDAPA and post-TDAPA add-on payment adjustment.

1
We note that all currently available phosphate binders are oral. Throughout this rule, we use the term “oral phosphate binders” when specifically discussing these drugs in certain contexts, such as the TDAPA or historical payment policies. The proposed CY 2027 ESRD PPS base rate increase would encompass all current and future phosphate binders, including a hypothetical future injectable phosphate binder or other form of administration.

2. Coverage and Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury (AKI)

On June 29, 2015, the President signed the Trade Preferences Extension Act of 2015 (TPEA) (Pub. L. 114-27). Section 808(a) of the TPEA amended section 1861(s)(2)(F) of the Act to provide coverage for renal dialysis services furnished on or after January 1, 2017, by a renal dialysis facility or a provider of services paid under section 1881(b)(14) of the Act to an individual

with AKI. Section 808(b) of the TPEA amended section 1834 of the Act by adding a new subsection (r) that provides for payment for renal dialysis services furnished by renal dialysis facilities or providers of services paid under section 1881(b)(14) of the Act to individuals with AKI at the ESRD PPS base rate beginning January 1, 2017. This rule proposes updates to the AKI dialysis payment rate for CY 2027. The AKI dialysis payment rate update would be indirectly affected by the proposed rebasing and revision of the ESRDB market basket under the ESRD PPS because the AKI dialysis payment rate is the ESRD PPS base rate, which is annually updated by the ESRDB market basket percentage increase factor minus a productivity adjustment, adjusted by the wage index. The proposed change to the ESRD PPS case mix adjusters for pediatric ESRD patients, the proposed expansion of the LVPA, and the proposed technical changes to the TDAPA and post-TDAPA add-on payment adjustment would not directly affect the CY 2027 AKI dialysis payment rate update.

3. End-Stage Renal Disease Quality Incentive Program (ESRD QIP)

The ESRD QIP is authorized by section 1881(h) of the Act. The Program establishes incentives for facilities to achieve high quality performance on measures with the goal of improving outcomes for ESRD beneficiaries. This proposed rule proposes the following changes to the ESRD QIP measure set beginning with PY 2029: replace the Hypercalcemia reporting measure with the Facility-Level Percentage of Chronic Hyperphosphatemia in Dialysis Patients (Hyperphosphatemia) clinical measure, update the National Healthcare Safety Network Bloodstream Infection (NHSN BSI) clinical measure, remove the Medication Reconciliation (MedRec) reporting measure, and remove the COVID-19 Vaccination Coverage Among Healthcare Personnel (HCP) reporting measure. Finally, this proposed rule requests public comment on the inclusion of the Dialysis Facility Discussion of Patient Life Goals (D-PaLS) Patient-Reported Outcome Performance Measure (PRO-PM) in the ESRD QIP.

4. Requests for Information (RFIs) on Advancing Dialysis Care

This proposed rule includes RFIs to solicit public input to inform potential future policy development related to increasing home dialysis uptake, improving palliative dialysis, and supporting alternative dialysis schedules. We seek to better understand how Medicare payment policy may support care for ESRD beneficiaries while maintaining the integrity of existing prospective payment systems, including the ESRD PPS, AKI dialysis payment, the Hospice benefit (section 1814(i) of the Act), and the Home Health PPS (section 1895 of the Act).

B. Summary of the Major Provisions

1. ESRD PPS

•
Proposed rebasing and revising of the End-Stage Renal Disease Bundled (ESRDB) market basket for CY 2027:
We are proposing to rebase and revise the ESRDB market basket to a 2024 base year, reflecting the most recent and complete set of Medicare cost report data as well as other publicly available data. In addition, we are proposing to update the labor-related share of the ESRD PPS base rate to reflect the proposed 2024 base year labor-related cost share weights designated in the ESRDB market basket.

•
Proposed update to the ESRD PPS base rate for CY 2027:
The proposed CY 2027 ESRD PPS base rate is $299.55, an increase from the CY 2026 ESRD PPS base rate of $281.71. This proposed amount reflects the application of the proposed wage index budget neutrality adjustment factor (1.00267), the proposed addition to the base rate of $15.96 to include phosphate binders, the budget neutrality factor for the proposed budget neutral changes to several payment adjustments (0.98783), and a proposed ESRDB market basket update of 1.6 percent as required by section 1881(b)(14)(F)(i)(I) of the Act, equaling $299.55 ((($281.71 + $15.96) × 1.00267 × 0.98783) × 1.016 = $299.55).

•
Proposed annual update to the wage index:
We adjust the ESRD PPS wage index on an annual basis using the most current mean hourly wage data for occupations related to the furnishing of renal dialysis services from the Bureau of Labor Statistics (BLS) Occupational Employment and Wage Statistics (OEWS) program and occupational mix data from the most recent full CY of freestanding ESRD facility Medicare cost reports. This wage index uses the latest core-based statistical area (CBSA) delineations to account for differing wage levels in areas in which ESRD facilities are located. For CY 2027, we are proposing to update the wage index based on this methodology and the latest available data.

•
Proposed annual update to the outlier policy:
We are proposing to update the outlier policy based on the most current data and established methodology. Accordingly, we are proposing to update the Medicare allowable payment (MAP) amounts for adult and pediatric patients for CY 2027 using the latest available CY 2025 claims data. We are proposing to update the ESRD outlier services fixed dollar loss (FDL) amount for pediatric patients using the latest available CY 2025 claims data and update the FDL amount for adult patients using the latest available claims data from CY 2023, CY 2024, and CY 2025. For pediatric beneficiaries, the FDL amount would increase from $162.43 to $206.43, and the MAP amount would increase from $50.19 to $60.86, as compared to CY 2026 values. For adult beneficiaries, the FDL amount would increase from $14.80 to $114.98, and the MAP amount would increase from $23.68 to $41.28, as compared to CY 2026 values. The 1.0 percent target for outlier payments was not achieved in CY 2025, as outlier payments represented approximately 0.9 percent of total Medicare payments. Our current estimates indicate outlier payments are above the 1.0 percent target for CY 2026, which also reflects the underlying utilization and cost trends that are contributing to increases in the MAP and FDL amounts.

•
Proposed update to the offset amount for the transitional add-on payment adjustment for new and innovative equipment and supplies (TPNIES) for CY 2027:
The proposed CY 2027 average per treatment offset amount for the TPNIES for capital-related assets that are home dialysis machines is $10.60. This proposed offset amount reflects the application of the proposed ESRDB market basket update of 1.6 percent ($10.43 × 1.016 = $10.60). There are no capital-related assets set to receive the TPNIES in CY 2027 for which this offset would apply.

•
Proposed update to the post-TDAPA add-on payment adjustment amounts:
We calculate the post-TDAPA add-on payment adjustment in accordance with 42 CFR 413.234(g). We are proposing modifications to the post-TDAPA add-on payment adjustment to calculate the adjustment quarterly and publish the post-TDAPA add-on payment adjustment amount via Change Request (CR). The estimated post-TDAPA add-on payment adjustment amount for Korsuva® is $0.1068 per treatment, which would be included in the calculation of the total post-TDAPA add-on payment adjustment for only the first quarter of CY 2027. Accordingly, for the first quarter of CY 2027, this amount would be incorporated into ESRD PPS payments for all dialysis treatments and adjusted by applicable patient-level adjustment factors. The estimated post-TDAPA add-on payment adjustment amount for DefenCath® is

$5.5951 per treatment, which would be included in the calculation for each quarter of CY 2027. The estimated post-TDAPA add-on payment adjustment amount for Vafseo® is $0.9437 per treatment, which would be included in the calculation for each quarter of CY 2027. We would finalize the post-TDAPA add-on payment adjustment amounts for each of these drugs, conditional on the continued receipt of ASP data, in the final rule. Should the proposal to update the post-TDAPA add-on payment adjustment amounts quarterly be finalized, we would only finalize the post-TDAPA add-on payment adjustment amount for the first quarter of CY 2027 in that final rule and would publish the amounts for the other quarters in CRs published after that final rule. The final post-TDAPA add-on payment adjustment amount for a given quarter would be added to ESRD PPS payments for all dialysis treatments furnished during that quarter and would be adjusted by applicable patient level adjustment factors.

•
Proposed incorporation of phosphate binders into the base rate:
We are proposing to incorporate phosphate binders into the ESRD PPS base rate at the end of the TDAPA period for the drugs, for CY 2027 and beyond. We are proposing to increase the ESRD PPS base rate by $15.96. This proposed amount would include an increase to account for operational costs, as discussed in section II.B.7. of this proposed rule.

•
Proposed expansion of the LVPA:
We are proposing to expand the LVPA to ESRD facilities which furnish up to 8,000 treatments per year. We are proposing to make payments based on 6 tiers of volume. We are proposing that this change be budget neutral with a budget neutrality factor of 0.98898.

•
Proposed modifications to certain adjustments for pediatric ESRD patients:
We are proposing to modify the case mix adjusters for pediatric ESRD patients. Additionally, we are proposing to allow ESRD facilities to receive the LVPA for pediatric ESRD patients. These proposals coincide with the end of the Transitional Pediatric ESRD Add-on Payment Adjustment (TPEAPA) as of December 31, 2026. We are proposing permanent policies to address payment for pediatric ESRD patients after the temporary increase through TPEAPA is no longer available.

•
Proposed modifications to the home and self-dialysis training add-on:
We are proposing to increase the home and self-dialysis training add-on payment adjustment to $138.22 from the current amount of $95.60. We are also proposing to allow training sessions during the onset period (the first 120 days of ESRD dialysis). For the reasons discussed in section II.B.10. of this proposed rule, we are proposing that this change be budget neutral with a budget neutrality factor of 0.99884.

•
Proposed modifications to the TDAPA and post-TDAPA add-on payment adjustment:
We are proposing that, when Average Sales Price (ASP) data is not usable because ASP is zero or negative, we would use the most recent usable quarter of ASP data, if available, as the basis for the TDAPA and the post-TDAPA add-on payment adjustment.

2. Payment for Renal Dialysis Services Furnished to Individuals With AKI

•
Proposed update to the dialysis payment rate for individuals with AKI:
We are proposing to update the AKI dialysis payment rate for CY 2027. The proposed CY 2027 payment rate is $299.55, which is the same as the proposed CY 2027 ESRD PPS base rate.

3. ESRD QIP

We are proposing to replace the Hypercalcemia reporting measure with the Hyperphosphatemia clinical measure beginning with PY 2029. Beginning with PY 2029, we are proposing to update the NHSN BSI clinical measure to use the most recently available national baseline data and to update the risk adjustment methodology. We are proposing to remove the MedRec reporting measure and the COVID-19 Vaccination Coverage Among HCP reporting measure from the ESRD QIP measure set beginning with PY 2029. We are also including an RFI on the potential inclusion of the Dialysis Facility Discussion of Patient Life Goals Patient-Reported Outcome Performance measure (D-PaLS PRO-PM) in the ESRD QIP.

4. RFIs on Advancing Dialysis Care

These RFIs solicit comments on increasing home dialysis uptake, improving palliative dialysis care, and supporting alternative dialysis schedules.

C. Summary of Costs and Transfers

In section VIII.C.5. of this proposed rule, we set forth a detailed analysis of the impacts that the proposed changes would have on affected entities and beneficiaries. Table 1 summarizes the impacts of each proposed change in this proposed rule.

EP26JN26.016

1. Impacts of the Proposed Updates to the ESRD PPS

The impact table in section VIII.C.5.a. of this proposed rule displays the estimated change in Medicare payments to ESRD facilities in CY 2027 compared to estimated Medicare payments in CY 2026. The overall impact of the proposed CY 2027 payment changes is projected to be a 1.1 percent increase in Medicare payments. Hospital-based ESRD facilities would have an estimated 2.0 percent increase in Medicare payments compared with freestanding ESRD facilities with an estimated 1.1 percent increase. We estimate that the aggregate Medicare program payments under the ESRD PPS would increase by approximately $70 million in CY 2027 compared to CY 2026 because of the proposed payment policies in this rule. Because of the projected 1.1 percent overall payment increase, we estimate there would be an increase in beneficiary coinsurance payments of 1.1 percent in CY 2027, which translates to approximately $20 million. This overall $90 million estimated increase, or 1.1 percent, includes the estimated impact of the proposed ESRD PPS market basket update of 1.6 percent ($130 million), as well as the estimated changes in payments associated with several proposed changes that are expected between CY 2026 and 2027. First, as discussed in section II.B.3.b. of this proposed rule, we estimate that outlier payments in CY 2026 will be approximately 3.0 percent of total ESRD PPS payments. Accordingly, the proposed increases to the FDL and MAP amounts for CY 2027 are projected to reduce ESRD PPS payments by approximately 1.9 percent ($150 million). At the same time, we estimate that approximately $430 million will be paid through the TDAPA for DefenCath®, Vafseo®, and phosphate binders in CY 2026. The end of the TDAPA periods for these drugs is projected to result in a corresponding decrease to CY 2027 payments of $430 million (5.5 percent), which is offset by the proposed 5.3 percent increase to the ESRD PPS base rate for phosphate binders and the estimated 2.0 percent increase in payments under the post-TDAPA add-on payment adjustment in CY 2027. The net difference between estimated CY 2026 TDAPA payments and estimated CY 2027 payments through the post-TDAPA add-on payment adjustment and the ESRD PPS base rate, including the incorporation of phosphate binders, is a 1.5 percent increase in payments to ESRD facilities. For CY 2027, we estimate total payments associated with the post-TDAPA add-on payment adjustment would be approximately $170 million.

Section 1881(b)(14)(D)(iv) of the Act provides that the ESRD PPS may include such other payment adjustments as the Secretary determines appropriate. Under this authority, CMS implemented § 413.234(c) to establish the TDAPA, a transitional drug add-on payment adjustment for certain new renal dialysis drugs and biological products; § 413.236 to establish the TPNIES, a transitional add-on payment adjustment for certain new and innovative equipment and supplies; and § 413.234(g) to establish the post-TDAPA add-on payment adjustment. The TDAPA, the TPNIES, and the post-TDAPA add-on payment adjustment are not budget neutral. As discussed in section II.D. of this proposed rule, there will be no new or continuing TPNIES payments for CY 2027. As discussed in section II.E. of this proposed rule, there are currently no continuing TDAPA payments in CY 2027.

2. Impacts of the Proposed Payment Rate for Renal Dialysis Services Furnished to Individuals With AKI

The impact table in section VIII.C.5.c. of this proposed rule displays the estimated change in Medicare payments to ESRD facilities for renal dialysis services furnished to individuals with AKI for CY 2027 compared to estimated Medicare payments for such services in CY 2026. The overall impact of the proposed CY 2027 changes is projected to be a 6.0 percent increase in Medicare payments for individuals with AKI. Hospital-based ESRD facilities would have an estimated 5.9 percent increase in Medicare payments compared with freestanding ESRD facilities that would have an estimated 6.0 percent increase. The overall impact reflects the effects of the proposed Medicare ESRD PPS payment rate update and the proposed CY 2027 ESRD PPS wage index and proposed labor related share of 63.5 percent. We estimate that the aggregate Medicare payments made to ESRD facilities for renal dialysis services furnished to individuals with AKI, at the proposed CY 2027 ESRD PPS base rate, would increase by approximately $5 million in CY 2027 compared to CY 2026.

3. Impacts of the PY 2029 ESRD QIP

We estimate that, as a result of previously finalized policies and changes to the ESRD QIP that we are proposing, the overall economic impact of the PY 2029 ESRD QIP would be approximately $125.4 million. The $125.4 million estimate for PY 2029 includes $102.1 million in costs associated with the collection of information requirements and approximately $23.3 million in payment reductions across all facilities.

4. RFIs on Advancing Dialysis Care

These RFIs do not propose any policy changes and therefore do not have a direct economic impact under Executive Order 12866.

II. Calendar Year (CY) 2027 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS)

A. Background

1. Statutory Background

On January 1, 2011, CMS implemented the ESRD PPS, a case-mix adjusted bundled PPS for renal dialysis services furnished by ESRD facilities, as required by section 1881(b)(14) of the Act, as added by section 153(b) of the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA) (Pub. L. 110-275). Section 1881(b)(14)(F) of the Act, as added by section 153(b) of MIPPA and amended by section 3401(h) of the Patient Protection and Affordable Care Act (Affordable Care Act) (Pub. L. 111-148), established that beginning with CY 2012, and each subsequent year, the Secretary shall annually increase payment amounts by an ESRD market basket percentage increase reduced by the productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act.

Section 632 of the American Taxpayer Relief Act of 2012 (ATRA) (Pub. L. 112-240) included several provisions that apply to the ESRD PPS. Section 632(a) of ATRA added section 1881(b)(14)(I) to the Act, which required the Secretary, by comparing per patient utilization data from 2007 with such data from 2012, to reduce the single payment for renal dialysis services furnished on or after January 1, 2014, to reflect the Secretary's estimate of the change in the utilization of ESRD-related drugs and biologicals
2

(excluding oral-only ESRD-related drugs). Consistent with this requirement, in the CY 2014 ESRD PPS final rule, we finalized $29.93 as the total drug utilization reduction and finalized a policy to implement the amount over a 3- to 4-year transition period (78 FR 72161 through 72170).

2
As discussed in the CY 2019 ESRD PPS final rule (83 FR 56922), we began using the term “biological products” instead of “biologicals” under the ESRD PPS to be consistent with FDA nomenclature. We use the term “biological products” in this proposed rule except when referencing specific language in the Act or regulations.

Section 632(b) of ATRA prohibited the Secretary from paying for oral-only

ESRD-related drugs and biologicals under the ESRD PPS prior to January 1, 2016. Section 632(c) of ATRA required the Secretary, by no later than January 1, 2016, to analyze the case-mix payment adjustments under section 1881(b)(14)(D)(i) of the Act and make appropriate revisions to those adjustments.

On April 1, 2014, the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113-93) was enacted. Section 217 of PAMA included several provisions that apply to the ESRD PPS. Specifically, sections 217(b)(1) and (2) of PAMA amended sections 1881(b)(14)(F) and (I) of the Act and replaced the drug utilization adjustment that was finalized in the CY 2014 ESRD PPS final rule (78 FR 72161 through 72170) with specific provisions that dictated the market basket update for CY 2015 (0.0 percent) and how the market basket percentage increase should be reduced in CY 2016 through CY 2018.

Section 217(a)(1) of PAMA amended section 632(b)(1) of ATRA to provide that the Secretary may not pay for oral-only ESRD-related drugs under the ESRD PPS prior to January 1, 2024. Section 217(a)(2) of PAMA further amended section 632(b)(1) of ATRA by requiring that in establishing payment for oral-only drugs under the ESRD PPS, the Secretary must use data from the most recent year available. Section 217(c) of PAMA provided that as part of the CY 2016 ESRD PPS rulemaking, the Secretary shall establish a process for (1) determining when a product is no longer an oral-only drug; and (2) including new injectable and intravenous products into the ESRD PPS bundled payment.

Section 204 of the Stephen Beck, Jr., Achieving a Better Life Experience Act of 2014 (ABLE) (Pub. L. 113-295) amended section 632(b)(1) of ATRA, as amended by section 217(a)(1) of PAMA, to provide that payment for oral-only renal dialysis drugs and biological products cannot be made under the ESRD PPS bundled payment prior to January 1, 2025. Effective January 1, 2025, all oral-only renal dialysis drugs and biological products are paid for under the ESRD PPS.

2. System for Payment of Renal Dialysis Services

Under the ESRD PPS, a single per-treatment payment is made to an ESRD facility for all the renal dialysis services defined in section 1881(b)(14)(B) of the Act and furnished to an individual for the treatment of ESRD in the ESRD facility or in a patient's home. We have codified our definition of renal dialysis services at § 413.171, which is in 42 CFR part 413, subpart H, along with other ESRD PPS payment policies.

The ESRD PPS base rate is adjusted for characteristics of both adult and pediatric patients and accounts for patient case-mix variability. The adult case-mix adjusters include five categories of age, body surface area, low body mass index, onset of dialysis, and four comorbidity categories (that is, pericarditis, gastrointestinal tract bleeding, hereditary hemolytic or sickle cell anemia, and myelodysplastic syndrome). A different set of case-mix adjusters are applied for the pediatric population. Pediatric patient-level adjusters include two age categories (under age 13, or age 13 to 17) and two dialysis modalities (that is, peritoneal dialysis (PD) or hemodialysis (HD) (§ 413.235(a) and (b)(1)).

The ESRD PPS provides four facility-level adjustments. The first payment adjustment reflects differences in area wage levels developed from core-based statistical areas (CBSAs) (§ 413.231). The second payment adjustment, the low volume payment adjustment (LVPA), accounts for ESRD facilities furnishing a low volume of dialysis treatments, with two tiers such that smaller low-volume facilities receive a higher payment adjustment (§ 413.232). The third payment adjustment accounts for ESRD facilities furnishing renal dialysis services in a rural area (§ 413.233(a)). The fourth payment adjustment, the non-contiguous areas payment adjustment (NAPA), accounts for non-labor costs for ESRD facilities in certain non-contiguous areas of the U.S. (§ 413.233(b)).

There are six additional payment adjustments under the ESRD PPS. The ESRD PPS provides adjustments, when applicable, for: (1) a training add-on for home and self-dialysis modalities (§ 413.235(c)); (2) an additional payment for high cost outliers due to unusual variations in the type or amount of medically necessary care (§ 413.237); (3) a TDAPA for certain new renal dialysis drugs and biological products (§ 413.234(c)); (4) a TPNIES for certain new and innovative renal dialysis equipment and supplies (§ 413.236(d)); (5) a transitional pediatric ESRD add-on payment adjustment (TPEAPA) of 30 percent of the per-treatment payment amount for renal dialysis services furnished to pediatric ESRD patients for CYs 2024 through 2026 (§ 413.235(b)(2));
3

and (6) a post-TDAPA add-on payment adjustment for certain new renal dialysis drugs and biological products after the end of the TDAPA period (§ 413.234(g)).

3
As the TPEAPA only applies for CYs 2024, 2025, and 2026, it will not apply for the CY 2027 payment year.

3. Updates to the ESRD PPS

Policy changes to the ESRD PPS are proposed and finalized annually in the
Federal Register
. The CY 2011 ESRD PPS final rule appeared in the August 12, 2010, issue of the
Federal Register
(75 FR 49030 through 49214). That rule implemented the ESRD PPS beginning on January 1, 2011, in accordance with section 1881(b)(14) of the Act, as added by section 153(b) of MIPPA, over a 4-year transition period. Since the implementation of the ESRD PPS, we have published annual rules to make routine updates, policy changes, and clarifications.

Most recently, we published a final rule, which appeared in the November 24, 2025, issue of the
Federal Register
, titled “Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, and End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model,” referred to herein as the “CY 2026 ESRD PPS final rule.” In that rule (90 FR 53068 through 53142), we updated the ESRD PPS base rate, wage index, and outlier policy for CY 2026. This rule also finalized modifications to the eligibility timeframe for the TDAPA and established a new payment adjustment for ESRD facilities in certain non-contiguous areas, the NAPA. For further detailed information regarding the CY 2026 updates and policy changes, see 90 FR 53068.

B. Proposed Provisions of the CY 2027 ESRD PPS Update

1. Proposed Rebasing and Revising of the ESRD Bundled (ESRDB) Market Basket; and Proposed CY 2027 Market Basket Percentage Increase, Productivity Adjustment, and Labor-Related Share (LRS)

a. Background

In accordance with section 1881(b)(14)(F)(i) of the Act, as added by section 153(b) of MIPPA and amended by section 3401(h) of the Affordable Care Act, beginning in 2012, the ESRD PPS payment amounts are required to be annually increased by an ESRD market basket increase factor and reduced by the productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act. The application of the productivity adjustment may result in the increase factor being less than 0.0 for a year and may result in payment rates for a year

being less than the payment rates for the preceding year. Section 1881(b)(14)(F)(i) of the Act also provides that the market basket increase factor should reflect the changes over time in the prices of an appropriate mix of goods and services included in renal dialysis services.

As required under section 1881(b)(14)(F)(i) of the Act, CMS developed an all-inclusive ESRD Bundled (ESRDB) input price index using CY 2008 as the base year effective for CY 2012 (75 FR 49151 through 49162). We subsequently rebased and revised the ESRDB input price index to a base year of CY 2012 in the CY 2015 ESRD PPS final rule (79 FR 66129 through 66136), and to a base year of CY 2016 in the CY 2019 ESRD PPS final rule (83 FR 56951 through 56964). In the CY 2023 ESRD PPS final rule (87 FR 67141 through 67157), we finalized a rebased ESRDB input price index to reflect a CY 2020 base year. Effective for CY 2027, we are proposing to rebase and revise the ESRDB market basket to a 2024 base year.

The ESRDB market basket is a fixed-weight, Laspeyres-type price index. A Laspeyres-type price index measures the change in price, over time, of the same mix of goods and services purchased in the base period. Any changes in the quantity or mix of goods and services (that is, intensity) purchased over time are not measured.

The index itself is constructed in three steps. First, a base period is selected (in this proposed rule, we propose to use 2024 as the base period) and total base period costs are estimated for a set of mutually exclusive and exhaustive spending categories, with the proportion of total costs that each category represents being calculated. These proportions are called cost weights. Second, each cost category is matched to an appropriate price or wage variable, referred to as a “price proxy.” In almost every instance, these price proxies are derived from publicly available statistical series that are published on a consistent schedule (preferably at least on a quarterly basis). Finally, the cost weight for each cost category is multiplied by the level of its respective price proxy. The sum of these products (that is, the cost weights multiplied by their price index levels) for all cost categories yields the composite index level of the market basket in a given period. Repeating this step for other periods produces a series of market basket levels over time. Dividing an index level for a given period by an index level for an earlier period produces a rate of growth in the input price index over that timeframe.

As previously noted, the market basket is described as a fixed-weight index because it represents the change in price over time of a constant mix (quantity and intensity) of goods and services needed to provide renal dialysis services. The effects on total costs resulting from changes in the mix of goods and services purchased after the base period are not measured. For example, an ESRD facility hiring more staff to accommodate the needs of patients would increase the volume of goods and services purchased by the ESRD facility but would not be factored into the price change measured by a fixed-weight ESRDB market basket. Only when the index is rebased would changes in the quantity and intensity be captured, with those changes being reflected in the cost weights. Therefore, we rebase the market basket periodically so that the cost weights reflect changes between base periods in the mix of goods and services that ESRD facilities purchase to furnish ESRD treatment.

We last rebased the ESRDB market basket cost weights effective for CY 2023 (87 FR 67141 through 67157), with 2020 data used as the base period for the construction of the market basket cost weights. For this CY 2027 ESRD PPS proposed rule, we propose to rebase the ESRDB market basket to reflect the 2024 cost structure for ESRD facilities and to revise applicable cost categories and price proxies used to determine the ESRDB market basket, as discussed in this proposed rule.

We refer to the proposed market basket as a CY market basket because the base period for all price proxies and weights is set to CY 2024 (that is, the average index level for CY 2024 is equal to 100). The major source data for the proposed ESRDB market basket is the 2024 Medicare cost reports (Form CMS-265-11, OMB No. 0938-0236), supplemented with 2022 data from the United States (U.S.) Census Bureau's Services Annual Survey (SAS) inflated to 2024 levels and the Bureau of Economic Analysis's (BEA) 2017 Benchmark Input-Output (I-O) data, inflated to 2024. The 2022 SAS data and 2017 Benchmark I-O data are the most recent year of detailed cost data published by the Census Bureau and the BEA for North American Industry Classification System (NAICS) Code 6214: Outpatient Care Centers, which is the 4-digit industry code that Kidney Dialysis Centers are classified within. We also are proposing to use May 2024 OEWS data from BLS for NAICS 6214 to further disaggregate the Wages and Salaries and Employee Benefits cost weights into occupational categories. We provide more detail on our proposed methodology in section II.B.1.b. of this proposed rule.

In the following section, we provide an overview of the proposed ESRDB market basket, describe the proposed methodologies for developing the cost weights, and provide information on the proposed price proxies. Then, we present the proposed CY 2027 market basket update and labor-related share based on the proposed 2024-based ESRDB market basket.

b. Proposed Rebasing and Revising of the ESRDB Market Basket

The terms “rebasing” and “revising,” while often used interchangeably, denote different activities. “Rebasing” means moving the base year for the structure of costs of an input price index (for example, in this proposed rule, we propose to shift the base year cost structure from 2020 to 2024). “Revising” means changing data sources or price proxies used in the input price index. For CY 2027, we are proposing to rebase the ESRDB market basket to reflect the 2024 cost structure of ESRD facilities and to revise the index, that is, make changes to cost categories or price proxies used in the index.

We invite public comments on our proposed methodology for deriving the proposed 2024-based ESRDB market basket discussed in this section of the proposed rule.

(1) Development of Cost Categories and Weights

(a) Use of Medicare Cost Report Data

The major source of cost data for developing the proposed rebased and revised ESRDB market basket cost weights is the 2024 Medicare cost reports. The 2024 Medicare cost reports are for those freestanding ESRD facilities whose cost reporting period began on or after October 1, 2023, and before October 1, 2024 (approximately 95 percent of freestanding ESRD facilities had a begin date on January 1, 2024, approximately 4 percent had a begin date prior to January 1, 2024, and approximately 1 percent had a begin date after January 1, 2024). Using this methodology allowed our sample to include ESRD facilities with varying cost report years including, but not limited to, the federal fiscal year (FY) or CY. We propose to use 2024 as the base year because we believe that the 2024 Medicare cost reports represent the most recent, complete set of Medicare cost report data available to develop cost weights for ESRD facilities at the time of rulemaking. We are proposing to maintain our policy of using data from freestanding ESRD facilities (which

account for over 95 percent of total ESRD facilities in CY 2024) because freestanding ESRD facility data reflects only the cost structure faced by the ESRD facility itself. In contrast, cost data for hospital-based ESRD facilities reflect the allocation of overhead from the entire institution.

The current set of instructions and associated forms for the Medicare cost reports for ESRD facilities (Form 265-11, OMB No. 0938-0236) can be found in Chapter 42 of the Provider Reimbursement Manual at the following website (
https://www.cms.gov/regulations-and-guidance/guidance/manuals/paper-based-manuals-items/cms021935
). We reviewed cost data from freestanding ESRD Medicare cost reports (CMS Form 265-11, OMB No. 0938-0236) for 2024 for each facility that reported costs and payments.

The major types of costs underlying the proposed 2024-based ESRDB market basket are derived from the Medicare cost reports (Form 265-11, OMB No. 0938-0236). Specifically, we propose to use the Medicare cost reports for eleven specific types of costs: Wages and Salaries; Employee Benefits; Pharmaceuticals (both Erythropoiesis Stimulating Agents (ESAs) and All Other Drugs in the ESRDB PPS bundled payment); Supplies; Laboratories; Housekeeping; Operations & Maintenance; Capital-related: Buildings and Fixtures; Capital-related: Moveable Equipment; Professional Liability Insurance; and Administrative & Other. Total Costs are defined as the sum of the eleven cost categories and associated costs identified previously.

To create a market basket that is representative of ESRDB facilities and to help ensure the major cost weights accurately reflect the percentage of total costs for furnishing ESRD treatment, we propose to apply edits to remove reporting errors and outliers. Specifically, edits were applied to include only Medicare cost reports that had total costs greater than zero. Total costs as reported on the Medicare cost report include those costs reimbursable under the ESRD PPS. For example, we excluded costs related to vaccines from total expenditures since these are not paid for under the ESRD PPS. Next, to reduce potential distortions from outliers in the calculation of the individual cost weights for the major expenditure categories for each cost category, values less than the 5th percentile or greater than the 95th percentile were excluded from the major cost weight computations. The resulting 2024 data set, after removing cost reports with total costs equal to or less than zero and excluding outliers, included information from approximately 6,514 independent ESRD facilities' cost reports from an available pool of 7,297 cost reports (roughly 89 percent of the universe). This sample of ESRD facilities is representative of the national universe of providers by ownership-type (proprietary, nonprofit, and government) and by urban/rural status.

Since each cost weight is determined independently, that is, the 5 percent trim is applied to each cost category, the resulting weights may not sum to 100.0. We propose normalizing the results proportionally so that the sum of each of the cost category weights will equal 100.0. A similar methodology was used to derive the major cost weights in the 2020-based ESRDB market basket.

We note that for the 2024 Medicare cost reports, a discrepancy was found with most Medicare cost reports submitted by a major large dialysis organization (LDO) where the Medicare cost report field designating the facility as a chain was completed incorrectly. Worksheet S, Part II, column 1, line 19 states “Are you part of a chain organization? Enter “Y” for yes or “N” for no. If yes, complete lines 20 through 22.” Many of these facilities entered “N”; however, they provided the location of the chain organization in lines Worksheet S, Part II, lines 20 through 22, indicating that the correct response to line 19 should have been “Y”. (We note that these facilities had also indicated being part of a chain organization in their prior year's cost report.) This led to reporting of Administrative & Other net expenses that was inconsistent with the chain designation. Worksheet A-3 provides for the computation of any needed adjustments to costs applicable to services, facilities, and supplies furnished to the facility by a related organization (by common ownership or control). This worksheet is potentially completed when a facility answers `Y' to Worksheet S, Part II. These adjustments to costs are transferred to Worksheet A, column 7 (to be reflected in Worksheet A, column 8) and, therefore, would then be reflected in the Administrative & Other net expenses.

To correct this misreporting, we first checked if the value reported on Worksheet A-3, Part B, column 1, line 1 was missing or 0, and whether the value reported on Worksheet A-3, Part B, column 6, line 1 was greater than zero. If these conditions were satisfied, we added the dollar ($) value of the related organization adjustment (Worksheet A-3, Part B, column 6, line 1) to the Administrative & Other cost center net expenses reported on Worksheet B, column 9, line 8.01. For any facility that didn't have a discrepancy, no adjustment was required to the Administrative & Other net expenses.

(i) Wages and Salaries Costs

We propose to determine Wages and Salaries costs as the sum of (1) direct patient care wages and salaries costs and (2) non-direct patient care wages and salaries costs. Direct patient care wages and salaries for 2024 are equal to the sum of costs from Worksheet B, column 4.01 (salaries for dialysis equipment technicians) and column 5 (direct patient care salaries), lines 8.01 through 17.03 (reimbursable cost centers) of the Medicare cost reports. Non-direct patient care wages and salaries are equal to the sum of all other wages and salaries costs for non-health workers, which we are proposing to derive using the following steps:

Step 1:
To capture the salary costs associated with non-direct patient care cost centers, we calculated salary percentages for non-direct patient care from Worksheet A of the Medicare cost reports. The estimated ratios were calculated as the ratio of salary costs (Worksheet A, columns 1 and 2) to total costs (Worksheet A, column 4). The salary percentages were calculated for seven distinct groups of cost centers: `Operations & Maintenance of Plant' combined with `Capital Related Costs-Renal Dialysis Equipment' (line 3 and 6), Housekeeping (line 4), Employee Health and Wellness (EH&W) Benefits for Direct Patient Care (line 8), Supplies (line 9 and 9.01), Laboratory (line 10), Administrative & General (line 11), and Drugs (line 12).

Step 2:
We then multiplied the salary percentages computed in step 1 by the total net costs for each corresponding reimbursable cost center as reported on Worksheet B. The Worksheet B totals are based on the sum of reimbursable costs reported on lines 8.01 through 17.03. For example, the salary percentage for Supplies (as measured by line 9 and 9.01 on Worksheet A) was applied to the total net costs for the Supplies cost center (the sum of costs reported on Worksheet B, column 7, lines 8.01 through 17.03). We complete this calculation for each of the seven groups of cost centers listed in step 1.

Step 3:
The estimated wages and salaries for each of the non-direct patient cost centers in step 2 were summed and then added to the direct patient care wages and salaries costs to calculate total Wages and Salaries costs.

(ii) Employee Benefits Costs

We propose to determine the Employee Benefits costs as the sum of direct patient care EH&W benefits (which we will refer to as direct patient care employee benefit costs) and estimated non-direct patient care employee benefit costs. Direct patient care employee benefit costs are reported on Worksheet B, column 6, lines 8.01 through 17.03 of the Medicare cost reports. Non-direct patient care employee benefit costs are not reported separately but are included in Worksheet A, column 3 (“Other”). We propose to derive the non-direct patient care benefit costs using the following steps:

Step 1:
We calculated the ratio of direct patient care employee benefit costs to direct patient care salaries for each facility. This ratio is calculated as direct patient care employee benefit costs (Worksheet B, column 6, lines 8.01 through 17.03) divided by the direct patient care wages and salaries costs (Worksheet B, columns 4.01 and 5, lines 8.01 through 17.03).

Step 2:
We estimate total salaries for all non-direct patient care cost centers except Administrative & Other. This would be the sum of direct patient care salaries plus estimated salaries for the non-direct patient care cost centers: EH&W benefits, pharmaceuticals, supplies, laboratory, housekeeping, and operation and maintenance of plant and equipment.

Step 3:
To determine estimated non-direct patient care employee benefit costs for all cost centers other than Administrative & Other we multiply the costs from step 2 by the ratio determined in step 1.

Step 4:
To calculate the employee benefit costs for Administrative & Other cost centers, we first estimate adjusted Administrative & Other costs by subtracting Professional Liability Insurance costs, estimated employee benefits costs for all workers except those associated with the Administrative & Other cost center (as derived in step 3), and Administrative & Other costs associated with Non-ESRD related costs or costs that are paid outside the bundle (Worksheet B, column 9, lines 5 through 7).

Step 5:
We estimate the adjusted Administrative & Other salary costs by multiplying the salary percentage for Administrative & Other cost centers (calculated in step 1 of the wages and salaries section) by the adjusted Administrative & Other costs calculated in step 4 of this section.

Step 6:
Total salaries are calculated by summing up the salary costs associated with the non-direct patient care cost centers (derived in step 2) and the adjusted Administrative & Other salary costs (derived in step 5).

Step 7:
To determine employee benefits costs for all employees, we multiply the total salaries (calculated in step 6) by the ratio of direct patient care benefits to direct patient care salaries (calculated in step 1).

We note that this proposed methodology for deriving total employee benefits costs from the Medicare cost report differs from the methodology we have used in prior ESRDB market baskets. Previously, we derived the Employee Benefits cost weight from Medicare cost report data for direct patient care employee benefits and supplemented with data from the 2012 U.S. Census Bureau's Services Annual Survey (SAS) for NAICS 621492, Kidney Dialysis Centers, which were inflated to the applicable base year (for example 2020) to account for non-direct patient care employee benefits. The U.S. Census Bureau discontinued publication of the SAS data for NAICS 621492 beginning in 2012 and discontinued publication of the SAS effective after the 2022 data release. For years between 2012 and 2022, the SAS data was only available at the four-digit NAICS level of detail, and we therefore continued to rely on the inflated 2012 data. We believe the proposed methodology is a technical improvement to the prior methodology used to derive the non-direct patient care employee benefits because it relies on more recent Medicare cost report data that are specific to ESRD facilities.

(iii) Pharmaceuticals Costs

The proposed 2024-based ESRDB market basket includes expenditures for all drugs, including formerly separately billable drugs and all other renal dialysis drugs that were covered under Medicare Part D before the ESRD PPS was implemented. We propose to determine the pharmaceuticals costs using data reported on Worksheet B; specifically, the sum of lines 8.01 through 17.03, for the following columns: column 11, “Drugs Included in Composite Rate,” column 12, “Erythropoiesis stimulating agents (ESAs)”; and column 13, “ESRD-Related and AKI -Related Drugs.” We did not include the drug costs for Non- ESRD Related Drugs, Supplies, and Labs as reported on line 5, column 10 or the AKI Non-Renal Related Drugs, Supplies, & Lab as reported on line 5.01 column 10 as these costs are not included in the ESRD PPS bundled payment amount. Section 1842(o)(1)(A)(iv) of the Act requires that influenza, pneumococcal, COVID-19, and hepatitis B vaccines described in paragraph (A) or (B) of section 1861(s)(10) of the Act be paid based on 95 percent of average wholesale price (AWP) of the drug. Since these vaccines are not paid for under the ESRD PPS, we did not include costs reported on Worksheet B, column 9, line 7 in the proposed 2024-based ESRDB market basket. Finally, to avoid double-counting, the pharmaceuticals costs are reduced by the estimated share of non-direct patient care wages and salaries associated with the applicable drug cost centers referenced previously. This resulted in a proposed 2024-based ESRDB market basket cost weight for Pharmaceuticals of 5.3 percent, with ESA costs accounting for 3.0 percentage points and All Other Drugs accounting for the remaining 2.3 percentage points.

(iv) Supplies Costs

We calculated the proposed Supplies costs using the costs reported in the Supplies cost center (Worksheet B, column 7, lines 8.01 through 17.03) of the Medicare cost report. To avoid double-counting, the Supplies costs were reduced to exclude the estimated share of non-direct patient care wages and salaries associated with this cost center.

(v) Laboratory Costs

We calculated the proposed Laboratory costs using the costs reported in the Laboratory cost center (Worksheet B, column 8, lines 8.01 through 17.03) of the Medicare cost report. To avoid double-counting, the Laboratory costs were reduced to exclude the estimated share of non- direct patient care wages and salaries associated with this cost center.

The Medicare cost report data include reported costs for Housekeeping, Operations & Maintenance, Capital-related: Buildings and Fixtures, and Capital-related: Moveable Equipment in a single cost center. We estimated the net costs for each of these four categories using the following steps.

Step 1:
We calculate the total net costs for Housekeeping, Operations & Maintenance, and Capital-related as the sum of costs reported on Worksheet B, column 3, lines 8.01 through 17.03).

Step 2:
For each of the four subcategories, we estimate the share of the total costs of each subcategory as follows:

• The Housekeeping share is determined based on the total costs for Housekeeping reported on Worksheet A, column 4, line 4 divided by the total costs for all four subcategories reported on Worksheet A, column 4, line 5.

• The Operations & Maintenance share is determined based on the total costs for Operations & Maintenance costs reported on Worksheet A, column 4, line 3 divided by the total costs for all four subcategories reported on Worksheet A, column 4, line 5.

•
The Capital-related:
Buildings and Fixtures share is determined based on the total costs for Capital-related buildings and fixtures reported on Worksheet A, column 4, line 1 divided by the total costs for all four subcategories reported on Worksheet A, column 4, line 5.

•
The Capital-related:
Moveable Equipment share is determined based on the total costs for Capital-related moveable equipment reported on Worksheet A, column 4, line 2 divided by the total costs for all four subcategories reported on Worksheet A, column 4, line 5.

(vi) Housekeeping Costs

The proposed Housekeeping costs are estimated by multiplying the housekeeping share determined in step 2 by the total net costs calculated in step 1. To avoid double-counting, the costs for the Housekeeping category were reduced to exclude the estimated share of non-direct patient care wages and salaries associated with this cost center.

(vii) Operations & Maintenance Costs

The proposed Operations & Maintenance costs are estimated by multiplying the operations & maintenance share determined in step 2 by the total net costs calculated in step 1. The operations & maintenance costs include the direct costs incurred in the operation and maintenance of the plant and equipment such as heat, light, water (excluding water treatment for dialysis purposes), air conditioning, and air treatment; the maintenance and repair of buildings, parking facilities, and equipment; painting; elevator maintenance; performance of minor renovation of buildings and equipment; and protecting employees, visitors, and facility property. To avoid double counting, the costs for the Operations & Maintenance category were reduced to exclude the estimated share of non-direct patient care wages and salaries associated with this cost center.

(viii) Capital-Related: Buildings and Fixtures Costs

The proposed Capital-related: Buildings and Fixtures costs are estimated by multiplying the capital-related buildings and fixtures share from step 2 by the total net costs calculated in step 1. The capital-related buildings and fixture costs include depreciation and lease costs for buildings and fixtures, property taxes, insurance costs, and capital improvements.

(ix) Capital-related: Moveable Equipment Costs

The proposed Capital-related: Moveable Equipment costs are estimated by multiplying the capital-related moveable equipment share from step 2 by the total net costs calculated in step 1. The capital-related moveable equipment costs include depreciation and lease costs for moveable equipment, property taxes, insurance costs, and capital improvements. Next, we sum the costs for capital-related moveable equipment to the Capital-related Renal Dialysis Equipment costs (Worksheet B, column 4, lines 8.01 through 17.03). We reasoned this delineation was particularly important given the critical role played by dialysis machines. Likewise, because price changes associated with buildings and fixtures could move differently than those associated with moveable equipment, we continue to believe that two capital-related cost categories are appropriate.

(x) Professional Liability Insurance Costs

We propose for the 2024-based ESRDB market basket to have a separate category for professional liability insurance (PLI) costs (often referred to as malpractice costs). The PLI costs are equal to the sum of premiums, paid losses, and self-insurance costs reported on Worksheet S, Part II, column 1, lines 15 through 17. For the 2020-based ESRDB market basket we did not create a separate cost category and the PLI costs were included with the Administrative & Other costs.

(xi) Administrative & Other Costs

We computed the proportion of total Administrative & Other costs using the Administrative & Other cost center data from Worksheet B, the sum of column 9, lines 8.01 through 17.03, less PLI costs and other costs reported in this cost center but paid separately from the ESRDB PPS, which include Non-ESRD Related Drugs, Supplies, & Lab (line 5); AKI Non-renal Related Drugs, Supplies, & Labs (line 5.01); Whole Blood and Packed Red Blood cells (line 6); and Vaccines (line 7). To avoid double-counting, the costs for the Administrative & Other category were also reduced to exclude the estimated share of non-direct patient care wages and salaries associated with this cost center and the estimated non-direct patient care employee benefits costs.

(b) Final Major Cost Category Computation

After we derived costs for the major cost categories for each provider using the Medicare cost report data as previously described, we propose to address data outliers using the following steps.

First, for each of the major cost weights, we propose to trim the data to remove outliers (a standard statistical process) by: (step 1) requiring that major costs (such as Wages and Salaries costs) and total costs be greater than zero; (step 2) dividing the costs for each of the eleven categories (calculated as previously described in this section) by total costs to obtain cost weights for each ESRD facility; and (step 3) excluding the top and bottom five percent of the major cost weight (for example, Wages and Salaries costs as a percent of total costs). We note that missing values are assumed to be zero consistent with the methodology for how missing values were treated in the 2020-based ESRDB market basket.

After the outliers have been removed, we sum the costs for each category across all remaining providers. We then divide this by the sum of total costs across all remaining providers to obtain a cost weight for the proposed 2024-based ESRDB market basket for the given category. This is the same methodology used for the 2020-based ESRDB market basket.

The trimming process is done individually for each cost category so that facilities excluded from one cost weight calculation are not automatically excluded from another cost weight calculation. We note that these proposed trimming methods are the same types of edits performed for the 2020-based ESRDB market basket, as well as other PPS market baskets (including but not limited to Inpatient Prospective Payment System (IPPS) operating market basket, Skilled Nursing Facility (SNF) market basket, and home health market basket). We note that for each of the cost weights we evaluated the distribution of providers and costs by ownership-type, and by urban/rural status. For all cost weights, the trimmed sample was nationally representative.

Table 2 presents the proposed 2024-based ESRDB market basket major cost weights as derived directly from the Medicare cost report data compared to the 2020-based ESRDB market basket major costs weights derived directly from the Medicare cost report data.

EP26JN26.017

From 2020 to 2024, the Wages and Salaries and Employee Benefits cost weights increased by 2.9 percentage points and 3.6 percentage points, respectively. The increase in the proposed 2024-based Wages and Salaries and Employee Benefits cost weights is the result of faster growth in labor costs compared to costs associated with the other market basket cost weights (such as Pharmaceutical costs). This faster growth is consistent with comments received during prior ESRD PPS rulemaking. The Pharmaceuticals cost weight as calculated directly from the Medicare cost reports decreased by 4.8 percentage points, which continues the downward trend in the Pharmaceuticals cost weight observed since the implementation of the ESRD PPS in 2011. We believe this falling Pharmaceuticals cost weight is attributable to three main inter-related factors: (1) reduced utilization per treatment of certain high-cost drug classes (such as ESAs), (2) a shift to more price‐competitive products, including generic drugs or biosimilars, and (3) facility‐level cost management and efficiency.

(c) Derivation of the Detailed Cost Weights

There are three instances where the proposed ESRDB market basket costs weights are further adjusted using secondary data sources. The first adjustment is to estimate contract labor costs, which would be reflected in the Administrative & Other cost weight of 16.8 percent shown in Table 2 derived from the Medicare cost report data. We propose to estimate the contract labor share of costs and reallocate those from Administrative & Other to Wages and Salaries and Employee Benefits. The second adjustment further disaggregates the Wages and Salaries and Employee Benefits weight, inclusive of contract labor costs, into occupational subcategories. The third adjustment is to further disaggregate the remaining Administrative & Other cost weight (less the contract labor cost weight) into further detail using data from the Bureau of Economic Analysis Benchmark Input-Output data.

(i) Contract Labor Costs

Contract labor costs are reported in the Medicare cost report; however, they are embedded in the Other Costs from the trial balance reported on Worksheet A, Column 3 and cannot be disaggregated. We propose the following methodology to derive the contract labor cost weight. Similar to the methodology used in the 2020-based ESRDB market basket, we are proposing to use data from the U.S. Census Bureau's Services Annual Survey (SAS) to estimate these costs for the 2024-based ESRDB market basket. We propose to use data from the 2022 SAS for NAICS 6214, Outpatient Care Centers, inflated to 2024 to estimate the contract labor weight for the 2024-based ESRDB market basket. Previously, we used the 2012 SAS data for NAICS 621492, Kidney Dialysis Centers inflated to the applicable base year. Since 2012 the SAS data is no longer available from the Census Bureau at the 6-digit NAICS level of detail, we believe that proposing to use the data for NAICS 6214 is a technically appropriate alternative as ESRD facilities would be included within this NAICS category and the data reflects the more recent experience of this industry's contract labor usage.

We propose to use the share of the total costs for NAICS 6214 expenses for Temporary staff and leased employee expense from the 2022 SAS. Using this data, the proposed 2024-based ESRDB Contract Labor cost weight is 2.1

percent. To avoid double counting these costs we are proposing to remove the 2.1 percent Contract Labor cost weight from the Administrative & Other cost weight (where we believe most contract labor costs would be reported). The resulting Administrative & Other Residual Cost weight is 14.7 percent, which reflects the 16.8 percent Administrative & Other cost weight from Medicare cost reports less the 2.1 percent Contract Labor cost weight.

As we did for the 2020-based ESRDB market basket (87 FR 67143), we propose to allocate contract labor costs to the Wages and Salaries and Employee Benefits cost weights based on their relative proportions for employed labor under the assumption that contract labor costs are comprised of both wages and salaries and employee benefits. The contract labor allocation proportion for wages and salaries is equal to the Wages and Salaries cost weight as a percent of the sum of the Wages and Salaries cost weight and the Employee Benefits cost weight. Using the 2024 Medicare cost report data, this percentage is 77 percent. Therefore, we propose to allocate 77 percent of the Contract Labor cost weight to the Wages and Salaries cost weight and 23 percent to the Employee Benefits cost weight. The 2020-based ESRDB market basket allocated 80 percent of the Contract Labor cost weight to the Wages and Salaries cost weight and 20 percent to the Employee Benefits cost weight.

Table 3 shows the Wages and Salaries and Employee Benefits cost weights after contract labor allocation for the 2020-based ESRDB market basket and the proposed 2024-based ESRDB market basket. In aggregate, the Compensation cost weight (calculated using more detailed decimal places) increased from 45.9 percent to 50.9 percent, or 5.0 percentage points.

EP26JN26.018

(ii) Disaggregation of Compensation Costs Into Occupational Categories

To further disaggregate the “Wages and Salaries” and “Employee Benefits” cost weights into four occupational subgroups (Health-Related, Management, Administrative, and Service), we propose to use the number of full time equivalents (FTEs) reported on Worksheet S-1, column 3, lines 22 through 35 of the Medicare cost reports and annual mean wages for the occupations within each group from the May 2024 BLS OEWS for NAICS 6214, Outpatient Care Centers.
4

4

https://www.bls.gov/oes/.

The ESRD Medicare cost report FTE categories assigned to the Health-Related subgroup include “Physicians,” “Registered Nurses,” “Licensed Practical Nurses,” “Nurses Aides,” “Technicians,” and “Dieticians”; assigned to the Management subgroup is “Management”; assigned to the Administrative subgroup is “Administrative”; and assigned to the Services subgroup are “Social Workers” and “Other”. For each FTE category, we estimate the mean annual wage from the May 2024 BLS OEWS data. We multiply the number of ESRD FTEs in each subgroup by the estimated mean annual wage. Table 4 shows the share of each FTE group's compensation (number of FTEs multiplied by the mean annual wage) to total compensation for the proposed 2024-based ESRD market basket and the 2020-based ESRDB market basket. Table 5 shows the Wages and Salaries and Employee Benefits occupational mix for the proposed 2024-based ESRDB market basket compared to the 2020-based occupational mix. The proposed 2024 occupational distribution shows a shift to more health-related FTEs and fewer Management and Administrative Support Occupation FTEs.

EP26JN26.019

EP26JN26.020

We propose to multiply the proposed occupational mix weights by the Wages and Salaries proposed cost weight and the Employee Benefits proposed cost weight (both inclusive of contract labor) to determine the occupational subgroups' weights for Wages and Salaries and Employee Benefits as shown in Table 6. This is similar to the methodology used in the 2020-based ESRDB market basket to derive these occupational subgroup weights.

(iii) Disaggregation of Administrative & Other Residual Cost Weight

To further divide the “Administrative & Other” residual cost weight estimated from the 2024 Medicare cost report data into more detailed cost categories, we propose to use the 2017 Benchmark I-O “The Use Table (Supply-Use Framework)” for NAICS 621400, Outpatient care Centers, published by the Bureau of Economic Analysis (BEA). These data are publicly available at the following website:
https://www.bea.gov/industry/input-output-accounts-data.
The BEA Benchmark I-O data are generally scheduled for publication every 5 years on a lagged basis, with the most recent data available for 2017. The 2017 Benchmark I-O data are derived from the 2017 Economic Census and are the building blocks for BEA's economic accounts. Therefore, they represent the most comprehensive and complete set of data on the economic processes or mechanisms by which output is produced and distributed.
5

BEA also produces Annual I-O estimates; however, while based on a similar methodology, these estimates reflect less comprehensive and less detailed data sources and are subject to revision when benchmark data become available. Instead of using the less detailed Annual I-O data, we propose to inflate the detailed 2017 Benchmark I-O data forward to 2024 by applying the annual price changes from the respective price proxies to the appropriate market basket cost categories that are obtained from the 2017 Benchmark I-O data and calculate the cost shares that each cost category represents using the inflated data. These resulting 2024 cost shares from this I-O based approach were applied to the “Administrative & Other” cost weight to obtain the detailed cost weights for the proposed 2024-based ESRDB market basket. For example, the cost for Paper & Printing represents 3.9 percent of the sum of the residual “All Other” 2017 Benchmark I-O Outpatient Care Center expenditures inflated to 2024. Therefore, the Paper & Printing cost weight represents 3.9 percent of the proposed 2024-based ESRDB market basket's “Administrative & Other” cost category (14.7 percent), yielding a Paper & Printing proposed cost weight of 0.6 percent in the proposed 2024-based ESRDB market basket (3.9 percent × 14.7 percent = 0.6 percent). For the 2020-based ESRDB market basket (87 FR 67145), we used a different data source to disaggregate the Administrative & Other residual cost weight. The prior method used data from the 2012 U.S. Census Bureau's SAS for NAICS 621492, inflated to the 2020 base year of the ESRDB market basket. As mentioned previously, this data is no longer produced or published by the Census Bureau and, therefore, we are proposing to use an alternative data source.

5

http://www.bea.gov/papers/pdf/IOmanual_092906.pdf.

Using this methodology, we propose to derive 12 detailed cost categories from the proposed 2024-based ESRDB market basket Administrative & Other cost weight of 14.7 percent. These categories are: (1) Electricity; (2) Natural Gas; (3) Rubber & Plastics; (4) Paper & Printing; (5) Miscellaneous Products; (6) Telephone and internet Service; (7) Administrative Services; (8) Financial Services; (9) Professional Fees: Labor-related; (10) Professional Fees: Nonlabor-related; (11) All Other

Services: Labor-related; (12) All Other Services: Nonlabor-related.

We note that the proposed cost category for Professional Fees: Labor-related reflects the proportion of ESRD facilities' professional fees expenses that we believe vary with local labor market. We conducted a survey of ESRD facilities in 2008 to better understand the proportion of contracted professional services that ESRD facilities typically purchase outside of their local labor market. These purchased professional services include functions such as accounting and auditing, management consulting, engineering, and legal services. Based on the survey results, we determined that, on average, 87 percent of professional services are purchased from local firms, and 13 percent are purchased from businesses located outside of the ESRD's local labor market. Thus, to derive the Professional Fees: Labor-related weight we allocate 87 percent of the expenses for Professional Fees for these selected services as labor-related; we note that 87 percent is the same percentage as used in prior years.

This proposed methodology allows for seven additional detailed cost categories than used in the 2020-based ESRDB market basket because the Benchmark I-O data is more comprehensive than the SAS data. The 2020-based ESRDB market basket included categories for Electricity, Natural Gas, Telephone, Professional Fees, and All Other Goods and Services.

Table 6 sets forth the proposed 2024-based ESRDB market basket, including the cost categories and their respective cost weights. For comparison purposes, the corresponding 2020-based ESRDB market basket cost weights also are listed.

BILLING CODE 4910-13-P

EP26JN26.021

BILLING CODE 4910-13-C

We invite public comments on our proposed methodology for deriving the proposed 2024-based ESRDB cost categories and weights.

(2) Proposed Price Proxies for the 2024-Based ESRDB Market Basket

After computing the proposed 2024-based cost weights for the ESRDB market basket, it was necessary to select appropriate wage and price proxies to reflect the rate of price change for each expenditure category. Except for the proxy for professional liability insurance (PLI), all proposed price proxies are based on BLS data and are grouped into one of the following BLS categories:

• Producer Price Indexes—Producer Price Indexes (PPIs) measure the average change over time in the selling prices received by domestic producers for their output. The prices included in the PPI are from the first commercial transaction for many products and some services (
https://www.bls.gov/ppi/
).

• Consumer Price Indexes—Consumer Price Indexes (CPIs) measure the average change over time in the prices paid by urban consumers for a market basket of consumer goods and services (
https://www.bls.gov/cpi/
). CPIs are only used when the purchases are similar to those of retail consumers rather than purchases at the producer level, or if no appropriate PPIs are available.

• Employment Cost Indexes—Employment Cost Indexes (ECIs) measure the rate of change in employee wage rates and employer costs for employee benefits per hour worked. These indexes are fixed-weight indexes and strictly measure the change in wage rates and employee benefits per hour. ECIs are superior to Average Hourly Earnings (AHE) as price proxies for input price indexes because they are not affected by shifts in occupation or industry mix, and because they measure pure price change and are available by both occupational group and by industry. The industry ECIs are based on the NAICS and the occupational ECIs are based on the Standard Occupational Classification System (SOC).

We evaluated the price proxies using the criteria of reliability, timeliness, availability, and relevance:

• Reliability. Reliability indicates that the index is based on valid statistical methods and has low sampling variability. Widely accepted statistical methods ensure that the data were collected and aggregated in a way that can be replicated. Low sampling variability is desirable because it indicates that the sample reflects the typical members of the population. (Sampling variability is variation that occurs by chance because only a sample was surveyed rather than the entire population.)

• Timeliness. Timeliness implies that the proxy is published regularly, preferably at least once a quarter. The market basket levels are updated quarterly, and therefore, it is important for the underlying price proxies to be up-to-date, reflecting the most recent data available. We believe that using proxies that are published regularly (at least quarterly, whenever possible) helps to ensure that we are using the most recent data available to update the market basket. We strive to use publications that are disseminated frequently, because we believe that this is an optimal way to stay abreast of the most current data available.

• Availability. Availability means that the proxy is publicly available. We prefer that our proxies are publicly available because this would help ensure that our market basket updates are as transparent to the public as possible. In addition, this enables the public to be able to obtain the price proxy data on a regular basis.

• Relevance. Relevance means that the proxy is applicable and representative of the cost category weight to which it is applied.

We believe the proposed PPIs, CPIs, and ECIs selected meet these criteria. Therefore, we believe that they continue to be the best proxy of price changes for the cost categories to which they would be applied.

In this proposed rule, we present a detailed explanation of the price proxies that we propose for each cost category weight.

(a) Health-Related Wages and Salaries

We propose to use the ECI for Wages and Salaries for All Civilian Workers in Hospitals (BLS series code #CIU1026220000000I) as the price proxy for health-related occupations. Of the two health-related ECIs that we considered (Hospitals and Health Care and Social Assistance), the wage distribution within the Hospital NAICS sector (622) is more closely related to the wage distribution of ESRD facilities than it is to the wage distribution of the Health Care and Social Assistance NAICS sector (62). This is the same price proxy used in the 2020-based ESRDB market basket.

(b) Management Wages and Salaries

We propose to use the ECI for Wages and Salaries for Private Industry Workers in Management, Business, and Financial (BLS series code #CIU2020000110000I). We believe this ECI is the most appropriate price proxy to measure the wages and salaries price growth of management personnel at ESRD facilities. This is the same price proxy used in the 2020-based ESRDB market basket.

(c) Administrative Wages and Salaries

We propose to use the ECI for Wages and Salaries for Private Industry Workers in Office and Administrative Support (BLS series code #CIU2020000220000I). We believe this ECI is the most appropriate price proxy to measure the wages and salaries price growth of administrative support personnel at ESRD facilities. This is the same price proxy used in the 2020-based ESRDB market basket.

(d) Services Wages and Salaries

We propose to use the ECI for Wages and Salaries for Private Industry Workers in Service Occupations (BLS series code #CIU2020000300000I). We believe this ECI is the most appropriate price proxy to measure the wages and salaries price growth of all other non-health related, non-management, and non-administrative service support personnel at ESRD facilities.

BLS does not publish ECI for Benefits price proxies for each wages and salaries ECI; however, where these series are not published, they can be derived by using the ECI for Total Compensation and the relative importance of wages and salaries with total compensation as published by BLS for each detailed ECI occupational index. Therefore, we propose to use these derived ECI benefit price proxies for each of the respective occupational benefit cost categories.

(e) Health-Related Benefits

We propose to use the ECI for Benefits for All Civilian Workers in Hospitals to measure price growth of this subcategory. This is calculated using the ECI for Total Compensation for All Civilian Workers in Hospitals (BLS series code #CIU1016220000000I) and the relative importance of Wages and Salaries within Total Compensation as published by BLS. We believe this constructed ECI series is technically appropriate for the reasons stated in the Wages and Salaries price proxy section. This is the same price proxy used in the 2020-based ESRDB market basket.

(f) Management Benefits

We propose to use the ECI for Benefits for Private Industry Workers in Management, Business, and Financial to measure price growth of this subcategory. This ECI is calculated using the ECI for Total Compensation for Private Industry Workers in Management, Business, and Financial (BLS series code #CIU2010000110000I) and the relative importance of wages

and salaries within total compensation. We believe this constructed ECI series is technically appropriate for the reasons stated in the Wages and Salaries price proxy section. This is the same price proxy used in the 2020-based ESRDB market basket.

(g) Administrative Benefits

We propose to use the ECI for Benefits for Private Industry Workers in Office and Administrative Support to measure price growth of this subcategory. This ECI is calculated using the ECI for Total Compensation for Private Industry Workers in Office and Administrative Support (BLS series code #CIU2010000220000I) and the relative importance of Wages and Salaries within Total Compensation. We believe this constructed ECI series is technically appropriate for the reasons stated in the wages and salaries price proxy section. This is the same price proxy used in the 2020-based ESRDB market basket.

(h) Services Benefits

We propose to use the ECI for Total Benefits for Private Industry Workers in Service Occupations (BLS series code #CIU2030000300000I) to measure price growth of this subcategory. We believe this ECI series is technically appropriate for the reasons stated in the Wages and Salaries price proxy section. This is the same price proxy used in the 2020-based ESRDB market basket.

(i) Electricity

We propose to use the PPI Commodity for Commercial Electric Power (BLS series code #WPU0542) to measure the price growth of this cost category. This is the same price proxy used in the 2020-based ESRDB market basket.

(j) Natural Gas

We propose to use the PPI Commodity for Commercial Natural Gas (BLS series code #WPU0552) to measure the price growth of this cost category. This is the same price proxy used in the 2020-based ESRDB market basket.

(k) ESAs

We propose to use the PPI Commodity for Biological Products, Excluding Diagnostic, for Human Use (which we will abbreviate as PPI-BPHU) (BLS series code #WPU063719) as the price proxy for the ESA drugs in the market basket. The PPI-BPHU measures the price change of prescription biologics, and ESAs would be captured within this index, if they are included in the PPI sample. Since the PPI relies on confidentiality with respect to the companies and drugs/biologicals included in the sample, we do not know if these drugs are indeed reflected in this price index. However, we believe the PPI-BPHU is an appropriate proxy to use because although ESAs may be a small part of the fuller category of biological products, we can examine whether the price increases for the ESA drugs are similar to the drugs included in the PPI- BPHU. We did this by comparing the historical price changes in the PPI- BPHU and the average sales price (ASP) for ESAs and found the cumulative growth to be consistent over the 2020 to 2024 timeframe. We will continue to monitor the trends in the prices for ESA drugs as measured by other price data sources to ensure that the PPI-BPHU is still an appropriate price proxy.

(l) All Other Drugs

For all other drugs included in the ESRD PPS bundled payment other than ESAs, we propose to use a blend of 47 percent of the PPI Commodity for Vitamin, Nutrient, and Hematinic Preparations (which we will abbreviate as PPI-VNHP) (BLS series code #WPU063807), and 53 percent of the PPI Commodity for Pharmaceuticals for Human Use, Prescription (which we will abbreviate as PPI-Pharmaceuticals) (BLS series code #WPUSI07003). We continue to believe that the PPI-VNHP is an appropriate price proxy for the iron supplements commonly used in the treatment of ESRD, and an analysis of claims data indicate that iron supplement costs and Vitamin D analogs account for about 47 percent of the All Other Drugs costs. For the remaining drugs represented in the All Other Drugs category we propose to use the PPI Commodity for Pharmaceuticals for Human Use, Prescription, which captures the inflationary price pressures for all types of prescription drugs rather than a single therapeutic category of drugs. Though this PPI measure includes a wide variety of prescription drugs, we believe it is technically appropriate to use a broad indicator of prescription drug price trends for three key reasons: (1) the more detailed PPI measure where we believe these types of non-ESA drugs would be captured would more likely reflect price trends not faced by ESRD facilities, such as cancer drugs, (2) there have been notable changes to the types and mix of drugs paid for under the ESRD PPS bundled payment since 2016, such as the inclusion of formerly oral-only drugs and the addition of AKI-related drugs, and (3) the potential for future changes to the types and mix of drugs that may be paid for under the ESRD PPS bundled payment. For these reasons, we believe that a broader drug index representing a larger mix of prescription drugs is technically appropriate to the proposed price proxy for this cost category. We will continue to monitor the relative share of costs for iron supplements and other types of drugs for this cost category to determine if the proposed 47/53 PPI blend warrants an adjustment, and if so, we would propose such an adjustment in future rulemaking. This is similar to the price proxy used in the 2020-based ESRDB market basket, but the composite weight was 50/50.

(m) Supplies

We propose to use the PPI Commodity for Surgical and Medical Instruments (BLS series code #WPU1562) to measure the price growth of this cost category. This is the same price proxy used in the 2020-based ESRDB market basket.

We believe this is a technically appropriate price proxy for this cost category. The Medicare cost report form instructions state that Supplies include the direct cost of total dialysis supplies used in furnishing dialysis services—for example, crit-lines, low volume lines and dialyzers, catheter kits, fistula needles and tape, saline flushes, bandages, chlorhexidine, tego caps for catheters, biopatch for catheter dressing, oxygen, suction, emergency supplies, monitors for vitals, and blood pressure cuffs. We are requesting comments on other price indexes that could be applicable to the costs reported in this category, as the instructions may not contain the exhaustive list of supply costs that ESRD facilities include in this category. Examples of potential other price proxies would include, but are not limited to, the PPI Commodity for Medical and surgical appliances and supplies (BLS series code WPU1563) and the PPI Commodity for Miscellaneous products, Personal safety equipment and clothing (BLS series code WPU1571).

(n) Laboratories

We propose to use the PPI Industry for Medical Laboratories (BLS series code #PCU621511621511) to measure the price growth of this cost category. This is the same price proxy used in the 2020-based ESRDB market basket.

(o) Paper & Printing

We propose to use a 25/75 blend of the PPI Commodity for Publications Printed Matter and Printing Material (BLS Series Code WPU094) and the PPI Commodity for Converted Paper and Paperboard Products (BLS series code WPU0915) to proxy the price growth of this cost category. The 2017 Benchmark I-O data shows that 25 percent of paper

and printing costs are for Printing (NAICS 323110) and the remaining costs are for Paper manufacturing (NAICS 322). The 2020-based ESRDB market basket did not have a separate cost category for paper and printing. These costs would have been included in the All Other Goods and Services cost category and proxied by the PPI—Final demand—Finished goods less foods and energy.

(p) Rubber & Plastics

We propose to use the PPI Commodity for Rubber and Plastic Products (BLS series code WPU07) to proxy the price growth of this cost category. The 2020-based ESRDB market basket did not have a separate cost category for Rubber & Plastics. These costs would have been included in the All Other Goods and Services cost category and proxied by the PPI—Final demand—Finished goods less foods and energy.

(q) Miscellaneous Products

We propose to use the PPI Commodity for Finished Goods Less Food and Energy (BLS series code WPUFD4131) to proxy the price growth of this cost category. This is the same price proxy used in the 2020-based ESRDB market basket as these costs were included in the All Other Goods and Services cost category.

(r) Telephone and Internet Service

We propose to use the CPI U.S. city average for Telephone Services (BLS series code #CUUR0000SEED) to measure the price growth of this cost category. This is the same price proxy used in the 2020-based ESRDB market basket.

(s) Housekeeping

We propose to use the PPI Commodity for Cleaning and Building Maintenance Services (BLS series code #WPU49) to measure the price growth of this cost category. This is the same price proxy used in the 2020-based ESRDB market basket.

(t) Operations & Maintenance

We propose to use the ECI for Total compensation for All Civilian workers in Installation, Maintenance, and Repair (BLS series code CIU1010000430000I) to measure the price growth of this cost category. This is the same price proxy used in the 2020-based ESRDB market basket.

(u) Administrative Services

We propose to use the ECI for Total Compensation for Private Industry Workers in Office and Administrative Support (BLS series code CIU2010000220000I) to proxy the price growth of this category. The 2020-based ESRDB market basket did not have a separate cost category for Administrative Services. These costs would have been included in the All Other Goods and Services cost category and proxied by the PPI—Final demand—Finished goods less foods and energy.

(v) Financial Services

We propose to use the ECI for Total Compensation for Private Industry Workers in Financial Activities (BLS series code CIU201520A000000I) to proxy the price growth of this cost category. The 2020-based ESRDB market basket did not have a separate cost category for Financial Services. These costs would have been included in the All Other Goods and Services cost category and proxied by the PPI—Final demand—Finished goods less foods and energy.

(w) Professional Fees: Labor-related

We propose to use the ECI for Total Compensation for Private Industry Workers in Professional and Related (BLS series code CIU2010000120000I) to measure the price growth of this cost category. This is the same price proxy used in the 2020-based ESRDB market basket; however, the 2012 SAS data did not provide enough detailed information to split the Professional Fees category between labor-related and nonlabor-related services.

(x) Professional Fees: Nonlabor-Related

We propose to use the ECI for Total Compensation for Private Industry Workers in Professional and Related (BLS series code CIU2010000120000I) to measure the price growth of this cost category. This is the same price proxy used in the 2020-based ESRDB market basket; however, the 2012 SAS data did not provide enough detailed information to split the professional fees category between labor-related and nonlabor-related services.

(y) All Other Services: Labor-Related

We propose to use the ECI for Total Compensation for Private Industry Workers in Service Occupations (BLS series code CIU2010000300000I) to proxy the price growth of this cost category. The 2020-based ESRDB market basket did not have a separate cost category for All Other Services: Labor-related. These costs would have been included in the All Other Goods and Services cost category and proxied by the PPI—Final demand—Finished goods less food and energy.

(z) All Other Services: Nonlabor-Related

We propose to use the CPI for All Items Less Food and Energy (BLS series code CUUR0000SA0L1E) to proxy the price growth of this cost category. We believe that using the CPI for All Items Less Food and Energy avoids double counting of changes in food and energy prices as they are not included in the ESRD PPS (food) or are already captured elsewhere in the market basket (energy). This is the same price proxy used in other CMS market baskets, such as the IPPS, SNF, Long-term Care Hospital (LTCH), Inpatient Rehabilitation Facility (IRF), and Inpatient Psychiatric Facility (IPF), to proxy the growth in the remaining “All Other Services” cost category. The 2020-based ESRDB market basket did not have a separate cost category for All Other Services: Nonlabor-related, these costs would have been included in the All Other Goods and Services cost category and proxied by the PPI—Final demand—Finished goods less food and energy.

(aa) Professional Liability Insurance

Unlike the other price proxies that are based on publicly available price indexes from BLS and other public sources, the proxy for PLI is based on data collected directly by CMS from a sample of commercial insurance carriers. We propose to use the CMS Physician PLI index to measure the price growth of this cost category in the proposed 2024-based ESRDB market basket. This is the same proxy used in the Medicare Economic Index (MEI) and the Home Health market basket. As detailed in the CY 2014 Physician Fee Schedule (PFS) final rule (78 FR 74271), a 2012 MEI Technical Panel expressed that the current index appropriately reflects the price changes in premiums throughout the industry.

(ab) Capital-Related: Buildings and Fixtures

We propose to use the PPI for Lessors of Nonresidential Buildings (BLS series code PCU531120531120) to measure the price growth of this cost category in the proposed 2024-based ESRDB market basket. This is the same proxy used in the 2020-based ESRDB market basket.

(ac) Capital-Related: Moveable Equipment

We propose to use the PPI Commodity for Electrical Machinery and Equipment (BLS series code #WPU117) to measure the price growth of this cost category. This is the same price proxy used in the 2020-based ESRDB market basket.

Table 7 shows all the proposed price proxies for the proposed 2024-based ESRDB Market Basket as well as

whether the price proxy was used in the 2020-based ESRDB market basket. As discussed in section II.B.1.b.(1)(b)(iii) of this proposed rule, for the proposed 2024-based ESRDB market basket we are proposing additional cost categories compared to the 2020-based ESRDB market basket. Therefore, in Table 7, the cost category expenses listed as n/a were included in the All Other Goods and Services cost category of the 2020-based ESRDB market basket and were proxied by the PPI Final demand—Finished goods less foods and energy.

BILLING CODE 4910-13-P

EP26JN26.022

EP26JN26.023

We invite public comments on our proposed price proxies for the proposed 2024-based ESRDB market basket.

(3) Proposed 2024-Based ESRDB Market Basket Percentage Increase Results

A comparison of the yearly differences of increase factors from CY 2021 to CY 2030 for the 2020-based ESRDB market basket and the proposed 2024-based ESRDB market basket is shown in Table 8. The proposed CY 2027 ESRDB market basket increase factor would be the same if we continued to use the 2020-based ESRDB market basket.

EP26JN26.024

BILLING CODE 4910-13-C

Over the CY 2021 through CY 2025 timeframe, the average percent change of the proposed 2024-based ESRDB market basket is 3.7 percent, the same as the average percent change of the 2020-based ESRDB market basket. For CY 2027, the proposed 2024-based ESRDB market basket is projected to increase 2.6 percent, which is the same projected increase as the CY 2027 projected increase of the 2020-based ESRDB market basket. For the forecast period, CY 2026 through CY 2030, the proposed 2024-based ESRDB market basket percentage increase is on average the same 5-year average projected increase as the 2020-based ESRDB market basket.

c. Proposed Labor-Related Share for ESRD PPS

We define the labor-related share (LRS) as those expenses that are labor-intensive and vary with, or are influenced by, the local labor market. The labor-related share of a market basket is determined by identifying the national average proportion of operating costs that are related to, influenced by, or vary with the local labor market.

We propose to use the proposed 2024-based ESRDB market basket cost weights to determine the proposed labor-related share for ESRD facilities. Therefore, effective for CY 2027, we are proposing a labor-related share of 63.5 percent, compared to the current 55.2 percent that was based on the 2020-based ESRDB market basket cost weights, as shown in Table 9. These figures represent the sum of Wages and Salaries, Employee Benefits, Housekeeping, Operations & Maintenance, Administrative Services, Professional Fees: Labor-related, All Other Services: Labor-related and 46 percent of the weight for Capital-related: Buildings and Fixtures (details discussed later in this section). We used a similar methodology to calculate the 2020-based ESRDB market basket labor-related share.

EP26JN26.025

The proposed labor-related share for capital-related expenses reflects the proportion of ESRD facilities' capital-related expenses that we believe varies with local labor market wages (46 percent of ESRD facilities' Capital-related: Buildings and Fixtures expenses). Capital-related expenses are affected in some proportion by variations in local labor market costs (such as construction worker wages) that are reflected in the price of the capital asset. However, many other inputs that determine capital costs are not related to local labor market costs, such as interest rates. The 46-percent figure is based on regressions run for the inpatient hospital capital PPS in 1991 (56 FR 43375). We use a similar methodology to calculate capital-related expenses for the labor-related shares for rehabilitation facilities (70 FR 30233), psychiatric facilities, long-term care facilities, and skilled nursing facilities (66 FR 39585).

We invite public comments on our proposed labor-related share based on the proposed 2024-based ESRDB cost weights.

d. Proposed CY 2027 ESRD Market Basket Update

Under section 1881(b)(14)(F)(i) of the Act, beginning in CY 2012, the ESRD PPS payment amounts are required to be annually increased by an ESRD market basket percentage increase factor and reduced by the productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act. We propose to use the proposed 2024-based ESRDB market basket as described in section II.B.1.b. of this proposed rule to compute the CY 2027 ESRDB market basket percentage increase based on the best available data. Consistent with historical practice, we propose to estimate the ESRDB market basket percentage increase based on IHS Global Inc.'s (IGI) forecast using the most recently available data at the time of rulemaking. IGI is a nationally recognized economic and financial forecasting firm with which CMS contracts to forecast the components of the market baskets. As discussed in section II.B.1.d.(3) of this proposed rule, we are calculating the proposed ESRDB market basket update for CY 2027 based on the proposed ESRDB market basket percentage increase and the proposed productivity adjustment, following our longstanding methodology.

(1) Proposed CY 2027 ESRDB Market Basket Percentage Increase

Using this methodology and IGI's first quarter of 2026 forecast of the proposed 2024-based ESRDB market basket (with historical data through the fourth quarter of 2025), and consistent with our historical practice of estimating market basket increases based on the best available data, the proposed CY 2027 ESRDB market basket increase factor is 2.6 percent. We also propose that if more recent data becomes available after the publication of the proposed rule and before the publication of the final rule (for example, a more recent estimate of the market basket percentage increase), we would use such data to determine the CY 2027 ESRDB market basket percentage increase in the final rule, provided such data is appropriate (meaning methodologically consistent with the proposed approach, sufficiently complete, and available in time to be reasonably evaluated for the final rule).

(2) Proposed CY 2027 Productivity Adjustment

Under section 1881(b)(14)(F)(i) of the Act, as amended by section 3401(h) of the Affordable Care Act, for CY 2012 and each subsequent year, the ESRDB market basket percentage increase shall be reduced by the productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act. The statute defines the productivity adjustment to be equal to the 10-year moving average of changes in annual economy-wide, private nonfarm business multifactor productivity (as projected by the Secretary for the 10-year period ending with the applicable fiscal year (FY), year, cost reporting period, or other annual period), hereafter referred to as the “productivity adjustment”.

BLS publishes the official measures of productivity for the United States economy. The productivity measure referenced in section 1886(b)(3)(B)(xi)(II) of the Act is published by BLS as private nonfarm business total factor productivity ((TFP) previously referred to as multifactor productivity).
6

We refer readers to
https://www.bls.gov/productivity/
for the BLS historical published TFP data. A complete description of IGI's TFP projection methodology is available on CMS's website at
https://www.cms.gov/data-research/statistics-trends-and-reports/medicare-program-rates-statistics/market-basket-research-and-information.

6

https://www.bls.gov/productivity/notices/2021/mfp-to-tfp-term-change.htm.

Based on IGI's first quarter 2026 forecast, the proposed productivity adjustment for CY 2027 (the 10-year moving average growth of TFP for the period ending CY 2027) is 1.0 percentage point. Furthermore, we propose that if more recent data becomes available after the publication of this proposed rule and before the publication of the final rule (for example, a more recent estimate of the productivity adjustment), we would use such data, if appropriate, to determine the CY 2027 productivity adjustment in the final rule.

(3) Proposed CY 2027 ESRDB Market Basket Update

In accordance with section 1881(b)(14)(F)(i) of the Act, we propose to base the CY 2027 ESRDB market basket percentage increase on IGI's first quarter 2026 forecast of the proposed 2024-based ESRDB market basket. We propose to then reduce the ESRDB market basket percentage increase by the proposed productivity adjustment for CY 2027 based on IGI's first quarter 2026 forecast. Therefore, the proposed CY 2027 ESRDB market basket update is equal to 1.6 percent (proposed 2.6 percent ESRDB market basket percentage increase reduced by a proposed 1.0 percentage point productivity adjustment). Furthermore, as noted previously, we propose that if more recent data becomes available after the publication of this proposed rule and before the publication of the final rule (for example, a more recent estimate of the market basket percentage increase or productivity adjustment), we would use such data, if appropriate, to determine the CY 2027 ESRD market basket percentage increase and productivity adjustment in the final rule.

We invite public comment on our proposals for the CY 2027 ESRDB market basket percentage increase and productivity adjustment.

2. Proposed CY 2027 ESRD PPS Wage Indices

a. Background

Section 1881(b)(14)(D)(iv)(II) of the Act provides that the ESRD PPS may include a geographic wage index payment adjustment, such as the index referred to in section 1881(b)(12)(D) of the Act, as the Secretary determines to be appropriate. In the CY 2011 ESRD PPS final rule (75 FR 49200), we finalized an adjustment for wages at § 413.231. Specifically, we established a policy to adjust the labor-related portion of the ESRD PPS base rate to account for geographic differences in the area wage levels using an appropriate wage index, which reflects the relative level of hospital wages and wage-related costs in the geographic area in which the ESRD facility is located. As discussed in detail later in this section, we later implemented an ESRD PPS specific wage index methodology in the CY 2025 ESRD PPS final rule (89 FR 89108 through 89117). Under current policy, we use OMB's CBSA-based geographic area designations to define urban and rural areas and their corresponding wage index values (75 FR 49117).
7

OMB publishes bulletins regarding CBSA changes, including changes to CBSA numbers and titles. We most recently updated the CBSA delineations in the CY 2025 ESRD PPS final rule (89 FR 89117) to the OMB delineations as described in OMB Bulletin No. 23-01, beginning with the CY 2025 ESRD PPS wage index.
8

7
We define urban areas at § 413.231(b) as a Metropolitan Statistical Area or a Metropolitan division (in the case where a Metropolitan Statistical Area is divided into Metropolitan Divisions), as defined by OMB. Rural areas are defined as any area outside an urban area.

8

https://www.whitehouse.gov/wp-content/uploads/2023/07/OMB-Bulletin-23-01.pdf.

Under § 413.231(d), a wage index floor value of 0.6000 is applied under the ESRD PPS as a substitute wage index for areas with very low wage index values, as finalized in the CY 2023 ESRD PPS final rule (87 FR 67161). Currently, all areas with wage index values that fall below the floor are located in Puerto Rico and the U.S. Virgin Islands. However, the wage index floor value is applicable for any area that may fall below the floor. A further description of the history of the wage index floor under the ESRD PPS can be found in the CY 2019 ESRD PPS final rule (83 FR 56964 through 56967) and the CY 2023 ESRD PPS final rule (87 FR 67161).

An ESRD facility's wage index is applied to the LRS of the ESRD PPS base rate. In the CY 2023 ESRD PPS final rule (87 FR 67153), we finalized the use of a LRS of 55.2 percent. In the CY 2021 ESRD PPS final rule (85 FR 71436), we finalized a temporary policy which applied a 5 percent cap on any decrease in an ESRD facility's wage index from the ESRD facility's wage index from the prior CY. The transition would be phased in over 2 years, such that the reduction in an ESRD facility's wage index would be capped at 5 percent in CY 2021, and no cap would be applied to the reduction in the wage index for the second year, CY 2022. In the CY 2023 ESRD PPS final rule (87 FR

67161), we finalized a permanent policy under § 413.231(c) to apply a 5 percent cap on any decrease in an ESRD facility's wage index from the ESRD facility's wage index from the prior CY. As discussed in section II.B.1.c. of this proposed rule, we are proposing that the CY 2027 LRS to which the wage index would be applied is 63.5 percent. This proposed LRS is based on the proposed 2024-based ESRDB market basket as discussed in section II.B.1.b. of this proposed rule.

In the CY 2011 ESRD PPS final rule (75 FR 49116) and the CY 2011 final rule on Payment Policies Under the Physician Fee Schedule (PFS) and Other Revisions to Part B (75 FR 73486) we established an ESRD PPS wage index methodology to use the most recent pre-floor, pre-reclassified hospital wage data collected annually under the hospital inpatient prospective payment system (IPPS). Historically, the ESRD PPS wage index values have been calculated without regard to geographic reclassifications authorized for acute care hospitals under sections 1886(d)(8) and (d)(10) of the Act and utilized pre-floor hospital data that are not adjusted for occupational mix. In the CY 2025 ESRD PPS final rule (89 FR 89116) we finalized a new ESRD PPS wage index methodology which uses mean hourly wage data from the BLS OEWS. This wage data is then weighted by a national ESRD facility occupational mix (NEFOM) which is derived from FTE data from freestanding ESRD facility cost report data. Treatment data from ESRD facility cost reports is also used to weigh the mean hourly wage data when aggregating the wage data at a CBSA level. As set forth in § 413.196(d)(2), we update the ESRD PPS wage index using the most current wage data for occupations related to the furnishing of renal dialysis services from BLS and occupational mix data from the most recent full CY of Medicare cost reports submitted in accordance with § 413.198(b).

For a detailed explanation of the current ESRD PPS wage index methodology, see the discussion in the CY 2025 ESRD PPS final rule (89 FR 89108 through 89117), and for a detailed explanation of the steps we use to calculate the ESRD PPS wage index according to this methodology see Addendum C of the CY 2025 ESRD PPS proposed rule available at
https://www.cms.gov/medicare/payment/prospective-payment-systems/end-stage-renal-disease-esrd/esrd-payment-regulations-and-notices/cms-1805-p.

b. National ESRD Facility Occupational Mix

Table 10 presents the NEFOM alongside the BLS occupation titles and codes for the occupations related to the furnishing of renal dialysis services. In this proposed rule we present the NEFOM to aid interested parties in their reconstruction of the proposed ESRD PPS wage index, but the actual ESRD PPS wage index uses the total FTEs for each occupation as described in the calculation in Addendum C of the CY 2025 ESRD PPS proposed rule rather than the rounded percentages presented in Table 10. The data in Table 10 is based on data from CY 2024 freestanding ESRD facility cost reports.

EP26JN26.026

c. Proposed CY 2027 ESRD PPS Wage Index

For CY 2027, we propose to update the wage indices to account for updated wage levels in areas in which ESRD facilities are located using the ESRD PPS wage index methodology established in the CY 2025 ESRD PPS final rule (89 FR 89098 through 89107) and specified in § 413.196(d)(2). The ESRD PPS wage index is specific for ESRD facilities as it uses specific wage data weighted by an ESRD facility occupational mix; this differentiates the ESRD PPS wage index from other Medicare PPSs, several of which utilize the pre-floor, pre-reclassification IPPS wage index. We propose to use the most recent available BLS OEWS mean hourly wage data for various occupations related to the furnishing of renal dialysis services weighted by FTE data from CY 2024 freestanding ESRD facility cost reports. The ESRD PPS wage index values are calculated without regard to geographic reclassifications authorized under sections 1886(d)(8) and (d)(10) of the Act. For CY 2027, the updated wage data used in the analysis for this proposed rule are from the May 2026 release of the BLS OEWS, which represents data from six semiannual surveys spanning November 2022 through May 2025.
9

9

https://www.bls.gov/news.release/pdf/ocwage.pdf.

For CY 2027, we propose to update the ESRD PPS wage index to use the most recent available BLS OEWS wage data. We are proposing that if more recent data becomes available after the analysis performed for the publication of this proposed rule and before the publication of the final rule (for example, an update to the May 2025 BLS OEWS mean hourly wage data or more complete CY 2024 cost report data), we would use such data, if appropriate, to determine the CY 2027 ESRD PPS wage index in the final rule.

The proposed CY 2027 ESRD PPS wage index is set forth in Addendum A and provides a crosswalk between the final CY 2026 wage index and the proposed CY 2027 wage index. Addendum B provides an ESRD facility level impact analysis. Both Addendum A and Addendum B are available on the CMS website at
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ESRDpayment/End-Stage-Renal-Disease-ESRD-Payment-Regulations-and-Notices.

3. Proposed CY 2027 Update to the Outlier Policy

a. Background

Section 1881(b)(14)(D)(ii) of the Act requires that the ESRD PPS include a payment adjustment for high-cost outliers due to unusual variations in the type or amount of medically necessary care, including variability in the amount of ESAs necessary for anemia management. Some examples of the patient conditions that may be reflective of higher facility costs when furnishing dialysis care are frailty and obesity. A patient's specific medical condition, such as secondary hyperparathyroidism, may result in higher per treatment costs. The ESRD PPS recognizes that some patients require high-cost care, and we have codified the outlier policy and our methodology for calculating outlier payments at § 413.237.

Section 413.237(a)(1) enumerates the following items and services that are eligible for outlier payments as ESRD outlier services:

• Renal dialysis drugs and biological products that were or would have been, prior to January 1, 2011, separately billable under Medicare Part B.

• Renal dialysis laboratory tests that were or would have been, prior to January 1, 2011, separately billable under Medicare Part B.

• Renal dialysis medical/surgical supplies, including syringes, used to administer renal dialysis drugs and biological products that were or would have been, prior to January 1, 2011, separately billable under Medicare Part B.

• Renal dialysis drugs and biological products that were or would have been, prior to January 1, 2011, covered under Medicare Part D, including renal dialysis oral-only drugs effective January 1, 2025.

• Renal dialysis equipment and supplies, except for capital-related assets that are home dialysis machines (as defined in § 413.236(a)(2)), that receive the transitional add-on payment adjustment as specified in § 413.236 after the payment period has ended.
10

10
Under § 413.237(a)(1)(vi), as of January 1, 2012, the laboratory tests that comprise the Automated Multi-Channel Chemistry panel are excluded from the definition of outlier services.

• Renal dialysis drugs and biological products that are Composite Rate Services as defined in § 413.171.

In the CY 2011 ESRD PPS final rule (75 FR 49142), CMS stated that for purposes of determining whether an ESRD facility would be eligible for an outlier payment, it would be necessary for the ESRD facility to identify the actual ESRD outlier services furnished to the patient by line item (that is, date of service) on the monthly claim. Renal dialysis drugs, laboratory tests, and medical/surgical supplies that are recognized as ESRD outlier services were specified in Transmittal 2134, dated January 14, 2011.
11

We use administrative issuances and guidance to continually update the renal dialysis service items available for outlier payment via our quarterly update CMS Change Requests (CRs), when applicable. For example, we use these issuances to identify renal dialysis oral drugs that were or would have been covered under Part D prior to 2011 to provide unit prices for determining the imputed MAP amounts. In addition, we use these issuances to update the list of ESRD outlier services by adding or removing items and services that we determined, based on our monitoring efforts, are either incorrectly included or missing from the list.

11
Transmittal 2033 issued August 20, 2010, was rescinded and replaced by Transmittal 2094, dated November 17, 2010. Transmittal 2094 identified additional drugs and laboratory tests that may also be eligible for ESRD PPS outlier payment. Transmittal 2094 was rescinded and replaced by Transmittal 2134, dated January 14, 2011, which included one technical correction.
https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R2134CP.pdf.

Under § 413.237, an ESRD facility is eligible for an outlier payment if its imputed (that is, calculated) MAP amount per treatment for ESRD outlier services exceeds a threshold. In past years, the MAP amount has reflected the average estimated expenditure per treatment for services that were or would have been considered separately billable services prior to January 1, 2011. The threshold is equal to the ESRD facility's predicted MAP per treatment plus the fixed dollar loss (FDL) amount. As described in the following paragraphs, the ESRD facility's predicted MAP amount is the national adjusted average ESRD outlier services MAP amount per treatment, further adjusted for case-mix and facility characteristics applicable to the claim. We use the term “national adjusted average” in this section of this proposed rule to more clearly distinguish the calculation of the average ESRD outlier services MAP amount per treatment from the calculation of the predicted MAP amount for a claim. The average ESRD outlier services MAP amount per treatment is based on utilization from all ESRD facilities, whereas the calculation of the predicted MAP amount for a claim is based on the individual ESRD facility and patient characteristics of the monthly claim. In accordance with § 413.237(c), ESRD facilities are paid 80 percent of the per treatment amount by which the imputed MAP amount for outlier services (that is, the actual incurred amount) exceeds this threshold. ESRD facilities are eligible to receive outlier payments for treating both adult and pediatric dialysis patients.

In the CY 2011 ESRD PPS final rule and codified in § 413.220(b)(4), using 2007 data, we established the outlier percentage—which is used to reduce the per treatment ESRD PPS base rate to account for the proportion of the estimated total Medicare payments under the ESRD PPS that are outlier payments—at 1.0 percent of total payments (75 FR 49142 through 49143). We also established the FDL amounts that are added to the predicted outlier services MAP amounts. The outlier services MAP amounts and FDL amounts are different for adult and pediatric patients due to differences in the utilization of separately billable services among adult and pediatric patients (75 FR 49140). As we explained in the CY 2011 ESRD PPS final rule (75 FR 49138 through 49139), the predicted outlier services MAP amounts for a patient are determined by multiplying the adjusted average outlier services MAP amount by the product of the patient-specific case-mix adjusters applicable using the outlier services payment multipliers developed from the regression analysis used to compute the payment adjustments.

In the CY 2023 ESRD PPS final rule, we finalized an update to the outlier methodology to better target 1.0 percent of total Medicare payments (87 FR

67170 through 67177). We explained that for several years, outlier payments had consist

[Text truncated at 120,000 characters. The full text is on the page linked above.]

---

Source: Frix Law Library, https://www.frixlaw.com/law-library/documents/fr%3A2026-12925. Public record. Not legal advice.
